Systematic treatment based on evidence for malignant pheochromocytoma: one case report and Literature review

A 51-years-old male with malignant pheochromocytoma underwent resection of the right adrenal tumor in May 2007. The pathological diagnosis was pheochromocytoma, suspected of being malignant tendency, which contained neuroblastoma cells. Recurrence and metastasis was observed 4 years after the operation. During the treatment, 131Imetaiodobenzylguanidine (131I-MIBG) treatment, palliative cytoreductive surgery, somatostatin treatment, TKI (sunitinib) targeted therapy, combined chemotherapy was administered with the overall survival time reaching 87 months. Like literature reports, surgery is the main treatment of malignant pheochromocytoma, 131I-MIBG treatment is an effective method, molecular targeted therapy is the most promising therapy. Even so, treatment of malignant pheochromocytoma is still lack of unified standard, successful treatment requires large sample of clinical observation and a multidisciplinary team. Correspondence to: Professor Jiege Huo, Vice Director, Oncology Dept. Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, 100 Shizi Street, Nanjing, Jiangsu 210028, P.R. China, E-mail: hjg16688@163.com

[1]  Yasushi Tanaka,et al.  Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas , 2017, Hormones and Cancer.

[2]  W. Young,et al.  Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series , 2017, Annals of Surgical Oncology.

[3]  L. Fishbein.  Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment. , 2016, Hematology/oncology clinics of North America.

[4]  F. M. Martínez Martín,et al.  Complete Remission in Metastatic Pheochromocytoma Treated with Extensive Surgery , 2016, Cureus.

[5]  P. Mark,et al.  Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. , 2015, QJM : monthly journal of the Association of Physicians.

[6]  P. Madej,et al.  [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments]. , 2015, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[7]  Won Jin Kim,et al.  Incidentally Detected Inoperable Malignant Pheochromocytoma with Hepatic Metastasis Treated by Transcatheter Arterial Chemoembolization , 2014, Endocrinology and metabolism.

[8]  Mohamed A. Sherisher,et al.  Target Therapy in Metastatic Pheochromocytoma: Current Perspectives and Controversies , 2014, Oncology reviews.

[9]  Yoichi M Ito,et al.  Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. , 2014, Endocrine journal.

[10]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[11]  C. Lubitz,et al.  Diagnosis and management of pheochromocytoma. , 2014, Current problems in surgery.

[12]  K. Ishibashi,et al.  Sunitinib for refractory malignant pheochromocytoma: two case reports , 2014, International Urology and Nephrology.

[13]  A. Tabarin,et al.  One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[14]  E. Baudin,et al.  Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma , 2013, Current Oncology Reports.

[15]  V. Mazzaferro,et al.  Malignant pheochromocytoma and paraganglioma: future considerations for therapy. , 2013, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[16]  E. Baudin,et al.  Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. , 2012, The Journal of clinical endocrinology and metabolism.

[17]  P. Levillain,et al.  Malignant pheochromocytoma: new malignancy criteria , 2012, Langenbeck's Archives of Surgery.

[18]  C. Demicco,et al.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge , 2012, Langenbeck's Archives of Surgery.

[19]  A. Harari,et al.  Malignant pheochromocytoma: a review. , 2011, American journal of surgery.

[20]  W. Scherbaum,et al.  Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma , 2011, Molecular and Cellular Endocrinology.

[21]  Herb Chen,et al.  The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer , 2010, Pancreas.

[22]  R. Heshmat,et al.  Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. , 2010, Pathology, research and practice.

[23]  H. Lehnert,et al.  Treatment of Malignant Pheochromocytoma , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[24]  Eva Forssell-Aronsson,et al.  Aspects on Radionuclide Therapy in Malignant Pheochromocytomas , 2006, Annals of the New York Academy of Sciences.

[25]  S. Schulz,et al.  Immunohistochemical Determination of Somatostatin Receptor Subtypes 1, 2A, 3, 4, and 5 in Various Adrenal Tumors , 2004, Endocrine research.

[26]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[27]  C. Haglund,et al.  VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  L. Thompson.  Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.

[29]  L. Peyrin,et al.  [Malignant pheochromocytoma]. , 1979, Archives des maladies du coeur et des vaisseaux.